EyeGate Pharmaceuticals reported a $3.377 million net loss in the third quarter, compared with a $1.356 million net loss in the third quarter of 2015, according to a company press release.A phase 3 confirmatory trial of EGP-437 for the treatment of ant…
Combination of squalamine, ranibizumab improves BCVA in eyes with retinal vein occlusion
Patients with macular edema secondary to retinal vein occlusion who received a combination of squalamine and ranibizumab had a better improvement in best corrected visual acuity than patients who received ranibizumab alone, according to a study. The si…
Aerie Pharmaceuticals to Participate in Three Investor Conferences in November
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company managemen…
NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report third quarter 2016 financial results after market close on Thursday, November 10. Management will hold an investment community conference call that day to discuss financial results and provide a Company update. DATE: Thursday,
Mount Sinai Health System introduces first enterprise-wide digital medicine care delivery system
Researchers in the Sinai App Lab at the Icahn School of Medicine at Mount Sinai have developed RxUniverse, the first enterprise-wide digital medicine care delivery system that enables physicians to digitally prescribe evidence-based mobile health appli…
GW scientist awarded $2.8 million NIH grant to continue research on corneal wound healing
George Washington University researcher Mary Ann Stepp, Ph.D., received a $2.8 million, five-year R01 grant from the National Institutes of Health to continue her 27 years of research on corneal wound healing.